Gyre Therapeutics, Inc. GYRE All Other Segments — Fair Value Adjustment Of Warrants
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s all other segments — fair value adjustment of warrants.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s all other segments — fair value adjustment of warrants?
- Gyre Therapeutics, Inc. (GYRE) reported all other segments — fair value adjustment of warrants of $0 in Q1 2026.
- What does all other segments — fair value adjustment of warrants mean?
- This metric reflects the periodic changes in the fair value of warrants issued by the company that are attributable to the 'All Other Segments' business unit. These adjustments are non-cash items that can significantly impact the reported financial results based on market conditions and stock price volatility. Investors track this to understand the impact of financial instruments on the segment's bottom line.